{"investor":{"slug":"tao-capital-partners","name":"Tao Capital Partners","website":null,"x_handle":null,"logo":"https://recentfunding.com/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkL3YxNDAzMDI3NzE1L3NubTNsbWwydHJkYmt0ZWVtMHV3LmpwZw","type":"fund","companies":1,"deals":0,"deals_12m":0,"deals_90d":0,"leads":0,"round_capital":0,"latest_deal":null},"profile":null,"fund_returns":[],"portfolio":[{"slug":"trigemx-bio","name":"TriGemX Bio","logo":"https://recentfunding.com/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkL2FjZmM2Y2RhYzBmNDQyNTdiZmNmNWQ4MmIzMGZhM2Fk","crypto":false,"categories":["health-bio"],"total_raised":94000000,"latest_raise":{"date":"2026-10-01","stage":"unknown","amount_usd":94000000,"source_url":"https://www.businesswire.com/news/home/20260930522593/en/TriGemX-Bio-Announces-%2494M-Financing-and-Initiation-of-Phase-3-Trials-for-Elismetrep-A-Potential-First-in-Class-Treatment-for-Migraine"},"rounds_with_investor":[],"backer_source_url":null}],"top_categories":[{"key":"health-bio","label":"Health and bio","companies":1,"share":1}],"allocation":{"stages":[],"years":[]},"co_investors":[]}